Literature DB >> 18316550

Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo.

Ayush Dagvadorj1, Robert A Kirken, Benjamin Leiby, James Karras, Marja T Nevalainen.   

Abstract

PURPOSE: Signal transducer and activator of transcription 5a/b (Stat5a/b) is the key mediator of prolactin effects in prostate cancer cells via activation of Janus-activated kinase 2. Prolactin is a locally produced growth factor in human prostate cancer. Prolactin protein expression and constitutive activation of Stat5a/b are associated with high histologic grade of clinical prostate cancer. Moreover, activation of Stat5a/b in primary prostate cancer predicts early disease recurrence. Here, we inhibited Stat5a/b by several different methodologic approaches. Our goal was to establish a proof of principle that Stat5a/b is critical for prostate cancer cell viability in vitro and for prostate tumor growth in vivo. EXPERIMENTAL
DESIGN: We inhibited Stat5a/b protein expression by antisense oligonucleotides or RNA interference and transcriptional activity of Stat5a/b by adenoviral expression of a dominant-negative mutant of Stat5a/b in prostate cancer cells in culture. Moreover, Stat5a/b activity was suppressed in human prostate cancer xenograft tumors in nude mice. Stat5a/b regulation of Bcl-X(L) and cyclin D1 protein levels was shown by antisense suppression of Stat5a/b protein expression followed by Western blotting. RESULTS AND
CONCLUSIONS: We show here that inhibition of Stat5a/b by antisense oligonucleotides, RNA interference, or adenoviral expression of dominant-negative Stat5a/b effectively kills prostate cancer cells. Moreover, we show that Stat5a/b is critical for human prostate cancer xenograft growth in nude mice. The effects of Stat5a/b on the viability of prostate cancer cells involve Stat5a/b regulation of Bcl-X(L) and cyclin D1 protein levels but not the expression or activation of Stat3. This work establishes Stat5a/b as a therapeutic target protein for prostate cancer. Pharmacologic inhibition of Stat5a/b in prostate cancer can be achieved by small-molecule inhibitors of transactivation, dimerization, or DNA binding of Stat5a/b.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316550     DOI: 10.1158/1078-0432.CCR-07-2024

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  49 in total

1.  Effects of metoclopramide on mRNA levels of steroid 5α-reductase isozymes in prostate of adult rats.

Authors:  Pilar Sánchez; Jesús M Torres; Beatriz Castro; José F Frías; Esperanza Ortega
Journal:  J Physiol Biochem       Date:  2012-07-18       Impact factor: 4.158

2.  Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.

Authors:  Bassem R Haddad; Andrew Erickson; Vindhya Udhane; Peter S LaViolette; Janice D Rone; Markku A Kallajoki; William A See; Antti Rannikko; Tuomas Mirtti; Marja T Nevalainen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-07-10       Impact factor: 4.254

3.  Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy.

Authors:  Tuomas Mirtti; Benjamin E Leiby; Junaid Abdulghani; Elina Aaltonen; Miia Pavela; Anita Mamtani; Kalle Alanen; Lars Egevad; Torvald Granfors; Andreas Josefsson; Par Stattin; Anders Bergh; Marja T Nevalainen
Journal:  Hum Pathol       Date:  2012-09-29       Impact factor: 3.466

Review 4.  Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer.

Authors:  Mateusz Koptyra; Shilpa Gupta; Pooja Talati; Marja T Nevalainen
Journal:  Int J Biochem Cell Biol       Date:  2011-06-17       Impact factor: 5.085

5.  LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis.

Authors:  Adam Ceroi; David Masson; Anne Roggy; Christophe Roumier; Cécile Chagué; Thierry Gauthier; Laure Philippe; Baptiste Lamarthée; Fanny Angelot-Delettre; Francis Bonnefoy; Sylvain Perruche; Sabeha Biichle; Claude Preudhomme; Elisabeth Macintyre; Laurent Lagrost; Francine Garnache-Ottou; Philippe Saas
Journal:  Blood       Date:  2016-10-04       Impact factor: 22.113

6.  Research resource: estrogen-driven prolactin-mediated gene-expression networks in hormone-induced prostatic intraepithelial neoplasia.

Authors:  Neville N C Tam; Carol Y Y Szeto; Johannes M Freudenberg; Amy N Fullenkamp; Mario Medvedovic; Shuk-Mei Ho
Journal:  Mol Endocrinol       Date:  2010-09-22

7.  Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors.

Authors:  Vindhya Udhane; Cristina Maranto; David T Hoang; Lei Gu; Andrew Erickson; Savita Devi; Pooja G Talati; Anjishnu Banerjee; Kenneth A Iczkowski; Kenneth Jacobsohn; William A See; Tuomas Mirtti; Deepak Kilari; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2019-09-23       Impact factor: 6.261

8.  Androgen-regulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor.

Authors:  Ayush Dagvadorj; Shyh-Han Tan; Zhiyong Liao; Luciane R Cavalli; Bassem R Haddad; Marja T Nevalainen
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

9.  Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.

Authors:  Lei Gu; Pooja Talati; Paraskevi Vogiatzi; Ana L Romero-Weaver; Junaid Abdulghani; Zhiyong Liao; Benjamin Leiby; David T Hoang; Tuomas Mirtti; Kalle Alanen; Michael Zinda; Dennis Huszar; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2014-02-27       Impact factor: 6.261

10.  Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.

Authors:  Jill Gallaher; Leah M Cook; Shilpa Gupta; Arturo Araujo; Jasreman Dhillon; Jong Y Park; Jacob G Scott; Julio Pow-Sang; David Basanta; Conor C Lynch
Journal:  Clin Exp Metastasis       Date:  2014-08-31       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.